دورية أكاديمية
Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation.
| العنوان: | Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation. |
|---|---|
| المؤلفون: | Wang Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China., Huang R; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China., Lu Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China., Liu M; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China., Mo R; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China. rmo@cpu.edu.cn. |
| المصدر: | Nature communications [Nat Commun] 2024 Jun 18; Vol. 15 (1), pp. 5176. Date of Electronic Publication: 2024 Jun 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Pub. Group |
| مواضيع طبية MeSH: | Hydrogels*/chemistry , Fas Ligand Protein*/metabolism , Fas Ligand Protein*/immunology , Transplantation, Homologous* , Mice, Inbred C57BL* , T-Lymphocytes, Regulatory*/immunology , Islets of Langerhans Transplantation*/methods , Skin Transplantation*/methods, Animals ; Mice ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/immunology ; Mesenchymal Stem Cells/immunology ; Mesenchymal Stem Cells/metabolism ; Mesenchymal Stem Cells/drug effects ; Mice, Inbred BALB C ; Graft Survival/drug effects ; Graft Survival/immunology ; Graft Rejection/prevention & control ; Graft Rejection/immunology ; Humans ; Male ; Apoptosis/drug effects |
| مستخلص: | The longevity of grafts remains a major challenge in allogeneic transplantation due to immune rejection. Systemic immunosuppression can impair graft function and can also cause severe adverse effects. Here, we report a local immuno-protective strategy to enhance post-transplant persistence of allografts using a mesenchymal stem cell membrane-derived vesicle (MMV)-crosslinked hydrogel (MMV-Gel). MMVs are engineered to upregulate expression of Fas ligand (FasL) and programmed death ligand 1 (PD-L1). The MMVs are retained within the hydrogel by crosslinking. The immuno-protective microenvironment of the hydrogel protects allografts by presenting FasL and PD-L1. The binding of these ligands to T effector cells, the dominant contributors to graft destruction and rejection, results in apoptosis of T effector cells and generation of regulatory T cells. We demonstrate that implantation with MMV-Gel prolongs the survival and function of grafts in mouse models of allogeneic pancreatic islet cells and skin transplantation. (© 2024. The Author(s).) |
| References: | Sci Transl Med. 2018 Apr 11;10(436):. (PMID: 29643233) Trends Immunol. 2022 Jan;43(1):8-21. (PMID: 34844848) Nat Rev Immunol. 2019 Jan;19(1):19-30. (PMID: 30429578) Nat Rev Endocrinol. 2023 Feb;19(2):68-69. (PMID: 36539606) Trends Biotechnol. 2021 Jan;39(1):90-104. (PMID: 32654775) Cell Res. 2008 Aug;18(8):846-57. (PMID: 18607390) Nat Rev Endocrinol. 2017 May;13(5):268-277. (PMID: 27834384) Adv Funct Mater. 2014 Nov 26;24(44):7053-7062. (PMID: 26213530) Cell Stem Cell. 2022 Nov 3;29(11):1515-1530. (PMID: 36332569) Lancet Respir Med. 2019 Mar;7(3):271-282. (PMID: 30738856) Nat Rev Mater. 2019 Jun;4(6):429-450. (PMID: 32617176) Nat Rev Cardiol. 2024 Jan;21(1):25-36. (PMID: 37452122) J Clin Invest. 2018 Aug 31;128(9):3906-3925. (PMID: 29952767) Am J Transplant. 2022 Nov;22(11):2571-2585. (PMID: 35897156) Nat Rev Endocrinol. 2019 Mar;15(3):172-188. (PMID: 30622369) Trends Pharmacol Sci. 2020 Sep;41(9):653-664. (PMID: 32709406) Am J Transplant. 2019 Jun;19(6):1614-1621. (PMID: 30801921) Nat Rev Dis Primers. 2020 Feb 13;6(1):11. (PMID: 32054846) Nat Mater. 2018 Jul;17(7):642-651. (PMID: 29784996) N Engl J Med. 2021 Aug 19;385(8):729-743. (PMID: 34407344) Transplantation. 2015 May;99(5):942-7. (PMID: 25651308) Sci Adv. 2020 Aug 28;6(35):eaba5573. (PMID: 32923626) Clin Infect Dis. 2021 Oct 5;73(7):e1302-e1317. (PMID: 32803228) Sci Adv. 2022 May 13;8(19):eabm9881. (PMID: 35559682) Cell Stem Cell. 2012 May 4;10(5):544-55. (PMID: 22542159) Sci Transl Med. 2022 Aug 3;14(656):eabg9170. (PMID: 35921475) Signal Transduct Target Ther. 2023 Mar 11;8(1):110. (PMID: 36906586) Nat Biomed Eng. 2020 Aug;4(8):814-826. (PMID: 32231313) Nat Biomed Eng. 2021 Sep;5(9):1038-1047. (PMID: 33903744) J Immunol. 2020 May 15;204(10):2840-2851. (PMID: 32253240) Nat Rev Drug Discov. 2022 Sep;21(9):655-675. (PMID: 35637318) Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):755-772. (PMID: 32681074) Nat Immunol. 2019 Apr;20(4):386-396. (PMID: 30890797) Nature. 2020 Oct;586(7830):606-611. (PMID: 32814902) Sci Adv. 2022 Dec 21;8(51):eabq3699. (PMID: 36542700) Cell Stem Cell. 2020 Oct 1;27(4):523-531. (PMID: 33007237) Nat Commun. 2021 Feb 1;12(1):723. (PMID: 33526787) Sci Transl Med. 2020 Jan 15;12(526):. (PMID: 31941825) Nat Rev Cancer. 2020 Jul;20(7):365-382. (PMID: 32415283) Transpl Int. 2021 Feb;34(2):233-244. (PMID: 33207013) Trends Mol Med. 2012 Feb;18(2):128-34. (PMID: 22118960) Cell Stem Cell. 2018 Jun 01;22(6):824-833. (PMID: 29859173) Nat Nanotechnol. 2018 Dec;13(12):1182-1190. (PMID: 30177807) Nat Rev Dis Primers. 2022 Jul 21;8(1):50. (PMID: 35864102) Nat Rev Drug Discov. 2019 Oct;18(10):749-769. (PMID: 31541224) Nat Mater. 2018 Aug;17(8):732-739. (PMID: 29867165) Am J Transplant. 2015 Jul;15(7):1748-54. (PMID: 25807965) Nat Rev Immunol. 2023 Oct;23(10):682-695. (PMID: 37185300) Nat Med. 2005 Jun;11(6):605-13. (PMID: 15937473) Nat Med. 2022 Apr;28(4):798-808. (PMID: 35288694) ACS Appl Mater Interfaces. 2022 Dec 19;:. (PMID: 36533683) Nat Biomed Eng. 2019 Feb;3(2):90-104. (PMID: 30944433) Sci Adv. 2022 Jul 22;8(29):eabn0071. (PMID: 35867788) Transplantation. 2021 Mar 1;105(3):484-495. (PMID: 32541562) Signal Transduct Target Ther. 2022 Mar 21;7(1):92. (PMID: 35314676) Nat Nanotechnol. 2022 Mar;17(3):319-330. (PMID: 35039683) |
| معلومات مُعتمدة: | 81971730, 82273876, 81673381 National Natural Science Foundation of China (National Science Foundation of China); 171028 Fok Ying Tong Education Foundation; SKLNMZZ202024 State Key Laboratory of Natural Medicines (SKLNM) |
| المشرفين على المادة: | 0 (Hydrogels) 0 (Fas Ligand Protein) 0 (B7-H1 Antigen) 0 (Cd274 protein, mouse) |
| تواريخ الأحداث: | Date Created: 20240618 Date Completed: 20240618 Latest Revision: 20240622 |
| رمز التحديث: | 20240622 |
| مُعرف محوري في PubMed: | PMC11189436 |
| DOI: | 10.1038/s41467-024-49135-x |
| PMID: | 38890279 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-49135-x |